Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies

Rationale: CD38 is a target for the therapy of multiple myeloma (MM) with monoclonal antibodies such as daratumumab and isatuximab. Since MM patients exhibit a high rate of relapse, the development of new biologics targeting alternative CD38 epitopes is desirable. The discovery of single-domain anti...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Theranostics
Päätekijät: Schriewer, Levin, Schütze, Kerstin, Petry, Katharina, Hambach, Julia, Fumey, William, Koenigsdorf, Julia, Baum, Natalie, Menzel, Stephan, Rissiek, Björn, Riecken, Kristoffer, Fehse, Boris, Röckendorf, Jana Larissa, Schmid, Joanna, Albrecht, Birte, Pinnschmidt, Hans, Ayuk, Francis, Kröger, Nicolaus, Binder, Mascha, Schuch, Gunter, Hansen, Timon, Haag, Friedrich, Adam, Gerhard, Koch-Nolte, Friedrich, Bannas, Peter
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Ivyspring International Publisher 2020
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7052896/
https://ncbi.nlm.nih.gov/pubmed/32194826
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.38533
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia